Revolution Medicines Files DEF 14A for 2024 Executive Comp
Ticker: RVMDW · Form: DEF 14A · Filed: Apr 29, 2025 · CIK: 1628171
| Field | Detail |
|---|---|
| Company | Revolution Medicines, Inc. (RVMDW) |
| Form Type | DEF 14A |
| Filed Date | Apr 29, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, DEF14A, equity-awards
TL;DR
Rev Med proxy shows exec comp details for 2024 - stock awards, vesting dates, fair value changes.
AI Summary
Revolution Medicines, Inc. filed a DEF 14A on April 29, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation and equity awards granted to its principal executive officers (PEO) and non-PEO/NEO members. Specific financial data regarding changes in the fair value of outstanding and unvested equity awards, as well as vesting dates for awards granted in prior years, are presented for the fiscal year 2024.
Why It Matters
This filing provides transparency into how Revolution Medicines compensates its top executives, including the value of stock and option awards, which can influence investor perception of management alignment and company strategy.
Risk Assessment
Risk Level: medium — DEF 14A filings are routine disclosures of executive compensation, but significant changes or unusual award structures could indicate underlying company performance or strategic shifts.
Key Numbers
- 2024-12-31 — Fiscal Year End (Reporting period for executive compensation details.)
- 20250429 — Filing Date (Date the DEF 14A was submitted to the SEC.)
Key Players & Entities
- Revolution Medicines, Inc. (company) — Filer
- 0001628171 (company) — Central Index Key
- 472029180 (company) — EIN
- DE (company) — State of Incorporation
- 700 SAGINAW DR (company) — Business Address
- REDWOOD CITY (company) — Business City
- CA (company) — Business State
- 94063 (company) — Business Zip
- 415-766-3638 (company) — Business Phone
FAQ
What is the total compensation reported for the Principal Executive Officer (PEO) in 2024?
The filing indicates data for PEO members for the fiscal year 2024, but specific dollar amounts for total compensation are not detailed in the provided excerpt.
What types of equity awards are detailed in this filing?
The filing details changes in the fair value of outstanding and unvested equity awards, as well as vesting dates for equity awards granted in prior years, for both PEO and non-PEO/NEO members.
When is the shareholder meeting for which this proxy statement is being filed?
The 'CONFORMED PERIOD OF REPORT' is listed as 20250626, indicating the period relevant to the shareholder meeting.
What is the SIC code for Revolution Medicines, Inc.?
The Standard Industrial Classification (SIC) code for Revolution Medicines, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Does the filing provide information on equity awards granted in previous years that vested in 2024?
Yes, the filing includes data related to 'ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember' for both PEO and non-PEO/NEO members for the fiscal year 2024.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 29, 2025 regarding Revolution Medicines, Inc. (RVMDW).